Vladimir Jankovic

Vladimir Jankovic is an experienced executive in the field of immuno-oncology, currently serving as Executive Director of TMCP Immuno-Oncology at Boehringer Ingelheim since September 2024. Previous roles include Head of Translational and Precision Medicine in Immuno-Oncology at Teva Pharmaceuticals and Senior Director of Precision Medicine at Regeneron Pharmaceuticals, where significant contributions were made in cancer immunotherapy, biomarker science, and early clinical development. Prior to these, Vladimir held various positions at Celgene, focusing on preclinical and translational development of cellular therapeutics, including a role as Director. Vladimir's career also includes experience as a Postdoctoral Research Associate at Memorial Sloan-Kettering Cancer Center, where research centered on hematopoietic stem cell biology. Education was obtained at the University of Belgrade, culminating in a Doctor of Medicine degree.